In this issue:
- Impact of early treatment and oxaliplatin discontinuation on CRC
- Intraoperative hyperthermic intraperitoneal chemotherapy for CRC
- Primary tumour side and treatment choice in RAS wild-type mCRC
- Panitumumab vs bevacizumab for RAS wild-type, left-sided mCRC
- Trifluridine/tipiracil + bevacizumab as second-line therapy for mCRC
- Preoperative chemotherapy for operable colon cancer
- Perioperative chemotherapy in CRC with peritoneal metastases
- Targeted therapy and survival outcomes in mCRC
- Adverse events with encorafenib + cetuximab in BRAF V600E-mutant mCRC
- PD-1/PD-L1 inhibitor + chemotherapy in MSI gastrointestinal cancers
Please login below to download this issue (PDF)